Survival Outcomes of US Patients Diagnosed with CMML over the Past Two Decades, Analysis from the SEER Database

Background: CMML is a rare and one of the most aggressive forms of leukemias with hybrid features of myeloproliferative neoplasms (MPN) and myelodysplastic neoplasms/syndromes (MDS). Given its rarity and the fact that CMML was categorized previously as MPN or MDS, the true incidence of CMML is unknown. To the best of our knowledge, the largest and most up to date study addressing the incidence and survival outcomes of patients with CMML in the United States covered a period from 2000 to 2013, with a sample size of 2,238 patients. The aim of this study is to investigate the clinical characteristics, survival outcomes, and independent prognostic factors of patients with CMML over the past two decades with a larger sample size. Methods: A total of 4,124 patients diagnosed with CMML, between 2000 and 2017, were ultimately enrolled in our study by retrieving data from the Surveillance, Epidemiology, and End Results (SEER) database. We analyzed demographics, clinical characteristics, and overall mortality (OM) as well as cancer-specific mortality (CSM) of HSTCL. Variables with a p value